Ascentage Pharma Group International (AAPG) Accumulated Expenses (2023 - 2025)

Ascentage Pharma Group International has reported Accumulated Expenses for 3 years, with the latest figure at $381949.0 in Q4 2025.

• For the quarter ending Q4 2025, Accumulated Expenses fell 81.52% year-over-year to $381949.0; the trailing twelve-month figure through Dec 2025 stood at $381949.0 (down 81.52% YoY), and the FY2025 full-year result was $387000.0, down 80.97% from the prior year.
• Accumulated Expenses for Q4 2025 stood at $381949.0, down from $2.1 million in the prior quarter.
• The five-year high for Accumulated Expenses was $2.1 million in Q4 2024, with the low at $381949.0 in Q4 2025.
• Historically, Accumulated Expenses has averaged $1.0 million across 3 years, with a median of $568049.4 in 2023.
• Annual changes were most pronounced in 2024 — Accumulated Expenses soared 263.87% — and 2025, when it sank 81.52%.
• Ascentage Pharma Group International's Accumulated Expenses stood at $568049.4 in 2023, then soared by 263.87% to $2.1 million in 2024, then slumped by 81.52% to $381949.0 in 2025.
• The last three Accumulated Expenses figures came in at $381949.0 (Q4 2025), $2.1 million (Q4 2024), and $568049.4 (Q4 2023), per Business Quant data.